214 related articles for article (PubMed ID: 20438801)
21. Rottlerin synergistically enhances imatinib-induced apoptosis of BCR/ABL-expressing cells through its mitochondrial uncoupling effect independent of protein kinase C-delta.
Kurosu T; Tsuji K; Kida A; Koyama T; Yamamoto M; Miura O
Oncogene; 2007 May; 26(21):2975-87. PubMed ID: 17130834
[TBL] [Abstract][Full Text] [Related]
22. [Study on mismatch repair genes of chronic myeloid leukemia].
Luo J; Peng ZG; Chen Y; Lai YR; Lu YY; Song SJ
Zhonghua Xue Ye Xue Za Zhi; 2006 Feb; 27(2):103-6. PubMed ID: 16732964
[TBL] [Abstract][Full Text] [Related]
23. Comparison of allele specific oligonucleotide-polymerase chain reaction and direct sequencing for high throughput screening of ABL kinase domain mutations in chronic myeloid leukemia resistant to imatinib.
Kang HY; Hwang JY; Kim SH; Goh HG; Kim M; Kim DW
Haematologica; 2006 May; 91(5):659-62. PubMed ID: 16627254
[TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
[TBL] [Abstract][Full Text] [Related]
25. BCR-ABL- and Ras-independent activation of Raf as a novel mechanism of Imatinib resistance in CML.
Hentschel J; Rubio I; Eberhart M; Hipler C; Schiefner J; Schubert K; Loncarevic IF; Wittig U; Baniahmad A; von Eggeling F
Int J Oncol; 2011 Sep; 39(3):585-91. PubMed ID: 21637917
[TBL] [Abstract][Full Text] [Related]
26. AID expression is correlated with Bcr-Abl expression in CML-LBC and can be down-regulated by As2O3 and/or imatinib.
Liu Z; Wu X; Duan Y; Wang Y; Shan B; Kong J; Ma X; Bao Y
Leuk Res; 2011 Oct; 35(10):1355-9. PubMed ID: 21570118
[TBL] [Abstract][Full Text] [Related]
27. Establishment and characterization of a novel imatinib-sensitive chronic myeloid leukemia cell line MYL, and an imatinib-resistant subline MYL-R showing overexpression of Lyn.
Ito T; Tanaka H; Kimura A
Eur J Haematol; 2007 May; 78(5):417-31. PubMed ID: 17432977
[TBL] [Abstract][Full Text] [Related]
28. A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.
Dash AB; Williams IR; Kutok JL; Tomasson MH; Anastasiadou E; Lindahl K; Li S; Van Etten RA; Borrow J; Housman D; Druker B; Gilliland DG
Proc Natl Acad Sci U S A; 2002 May; 99(11):7622-7. PubMed ID: 12032333
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
Okabe S; Tauchi T; Ohyashiki K
Clin Cancer Res; 2008 Oct; 14(19):6181-6. PubMed ID: 18829496
[TBL] [Abstract][Full Text] [Related]
30. Sonic hedgehog signaling regulates Bcr-Abl expression in human chronic myeloid leukemia cells.
Liao HF; Su YC; Zheng ZY; Jhih Cai C; Hou MH; Chao KS; Chen YJ
Biomed Pharmacother; 2012 Jul; 66(5):378-83. PubMed ID: 22397755
[TBL] [Abstract][Full Text] [Related]
31. Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
Retnakumari AP; Hanumanthu PL; Malarvizhi GL; Prabhu R; Sidharthan N; Thampi MV; Menon D; Mony U; Menon K; Keechilat P; Nair S; Koyakutty M
Mol Pharm; 2012 Nov; 9(11):3062-78. PubMed ID: 22971013
[TBL] [Abstract][Full Text] [Related]
32. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia.
Neviani P; Santhanam R; Oaks JJ; Eiring AM; Notari M; Blaser BW; Liu S; Trotta R; Muthusamy N; Gambacorti-Passerini C; Druker BJ; Cortes J; Marcucci G; Chen CS; Verrills NM; Roy DC; Caligiuri MA; Bloomfield CD; Byrd JC; Perrotti D
J Clin Invest; 2007 Sep; 117(9):2408-21. PubMed ID: 17717597
[TBL] [Abstract][Full Text] [Related]
33. Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr-Abl positive cell lines in vitro and in vivo.
Yuan X; Zhang Y; Zhang H; Jin J; Li X; Liu H; Feng Z; Chen X
Leuk Res; 2011 Feb; 35(2):237-42. PubMed ID: 20739063
[TBL] [Abstract][Full Text] [Related]
34. Activation of STAT5 confers imatinib resistance on leukemic cells through the transcription of TERT and MDR1.
Yamada O; Ozaki K; Furukawa T; Machida M; Wang YH; Motoji T; Mitsuishi T; Akiyama M; Yamada H; Kawauchi K; Matsuoka R
Cell Signal; 2011 Jul; 23(7):1119-27. PubMed ID: 21356308
[TBL] [Abstract][Full Text] [Related]
35. Resistance to daunorubicin-induced apoptosis is not completely reversed in CML blast cells by STI571.
Tabrizi R; Mahon FX; Cony Makhoul P; Lagarde V; Lacombe F; Berthaud P; Melo JV; Reiffers J; Belloc F
Leukemia; 2002 Jun; 16(6):1154-9. PubMed ID: 12040447
[TBL] [Abstract][Full Text] [Related]
36. Diverse mechanisms of mTOR activation in chronic and blastic phase of chronic myelogenous leukemia.
Stoklosa T; Glodkowska-Mrowka E; Hoser G; Kielak M; Seferynska I; Wlodarski P
Exp Hematol; 2013 May; 41(5):462-9. PubMed ID: 23395818
[TBL] [Abstract][Full Text] [Related]
37. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives.
Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A
Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109
[TBL] [Abstract][Full Text] [Related]
38. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration.
Campbell LJ; Patsouris C; Rayeroux KC; Somana K; Januszewicz EH; Szer J
Cancer Genet Cytogenet; 2002 Nov; 139(1):30-3. PubMed ID: 12547154
[TBL] [Abstract][Full Text] [Related]
39. Persistent activation of the Fyn/ERK kinase signaling axis mediates imatinib resistance in chronic myelogenous leukemia cells through upregulation of intracellular SPARC.
Fenouille N; Puissant A; Dufies M; Robert G; Jacquel A; Ohanna M; Deckert M; Pasquet JM; Mahon FX; Cassuto JP; Raynaud S; Tartare-Deckert S; Auberger P
Cancer Res; 2010 Dec; 70(23):9659-70. PubMed ID: 21098700
[TBL] [Abstract][Full Text] [Related]
40. A small molecule significantly inhibits the bcr/abl fusion gene at the mRNA level in human chronic myelogenous leukemia.
He Q; Dong J; Zhen H; Ying Y; Zhang J; Li Q; Li B; Zhou Y
Leuk Res; 2011 Aug; 35(8):1074-9. PubMed ID: 21163528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
